Low-Dose combo aims to tame bone marrow cancers with fewer side effects

NCT ID NCT05184842

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a low-dose weekly schedule of two drugs, decitabine and venetoclax, in people with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). The goal is to see if this gentler approach reduces treatment delays and side effects while still controlling the cancer. About 91 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Decitabine and Venetoclax
What this could lead to: If this works, it could offer a gentler treatment option for bone marrow cancers with fewer side effects.
What could go wrong: This is a small, early-phase trial (91 people) focused on tolerability, not yet proven to improve survival or remission rates. The low dose may also be less effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States
University of California Davis Health (UC Davis Health)
RECRUITING

Sacramento, California, 95817, United States
White Plains Hospital
RECRUITING

White Plains, New York, 10601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.